HeartSciences Technology Selected for Heart Screening of Irish Garda National Police Officers

Medical technology company, HeartSciences (Nasdaq: HSCS), has announced that its MyoVista® wavECGTM has been selected by Cardiact Ltd to be used in its heart screening program of members of the Association of Garda Sergeants and Inspectors (AGSI). The program will be conducted across Ireland and is due to commence on November 27, 2023.

In addition to the purchase of a MyoVista® device, Cardiact has placed an initial supplies order covering 2,400 patient tests.

Andrew Simpson, Chief Executive Officer of HeartSciences, commented, “We are delighted that the MyoVista® wavECG™ has been chosen for use in this heart screening program of Irish Garda officers.” 

Highlights

Cardiact is rolling out a newly established heart screening program for the AGSI, which represents sergeants and inspectors of the Garda Síochána national police service of Ireland.

HeartSciences also recently signed an agreement with the Icahn School of Medicine at Mount Sinai, which provides the company with what it believes is the largest AI-based ECG algorithm portfolio of any commercial organization.

The AI-ECG industry continues to make exciting progress, with the recent creation of a new FDA product classification for AI-ECG algorithms which HeartSciences expects to make clearance more structured and quicker under the 510(k) process.

HeartSciences has stated that it views AI-based ECG algorithms as the bridge that will allow front-line healthcare professionals to detect heart disease earlier and at a lower cost

The MyoVista® device is a resting 12-lead ECG that is designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging.

About HeartSciences

Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG’s clinical usefulness. Millions of ECGs are performed every week and the Company’s objective is to improve healthcare by making an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences’ first product candidate for FDA clearance, the MyoVista® wavECGTM, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test. The business model, which involves the use of the MyoVista® Device and consumables for each test, is expected to be “razor-razorblade” as the electrodes used with the MyoVista® are proprietary to HeartSciences, and new electrodes are required for every test performed.